Biocompatible lipid nanovehicles for preventive and therapeutic vaccine development DOI

Yaru Jia,

Ziran Zhou,

Luksika Jiramonai

и другие.

Coordination Chemistry Reviews, Год журнала: 2025, Номер 538, С. 216718 - 216718

Опубликована: Апрель 22, 2025

Язык: Английский

Application of in-silico approaches in subunit vaccines: Overcoming the challenges of antigen and adjuvant development DOI
Xue Tang,

Jiayin Deng,

Chun‐Ting He

и другие.

Journal of Controlled Release, Год журнала: 2025, Номер unknown, С. 113629 - 113629

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Breaking the barriers in effective and safe toll-like receptor stimulation via nano-immunomodulators for potent cancer immunotherapy DOI
Yaoqi Li, Yitian Chen, Yongan Tang

и другие.

Journal of Controlled Release, Год журнала: 2025, Номер unknown, С. 113667 - 113667

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
STING-activating pyroptotic nanoparticles for in situ pancreatic cancer vaccination and immunotherapy DOI
Shiyi Shao, Xiaohong Chen, Yuxuan Chen

и другие.

Science Bulletin, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
Chiral Aluminum Oxyhydroxide Supraparticles as Adjuvants DOI
Zongda Li,

Aihua Qu,

Chuanlai Xu

и другие.

Advanced Materials, Год журнала: 2025, Номер unknown

Опубликована: Апрель 16, 2025

Abstract Aluminum‐based adjuvants dominate global vaccine formulations owing to their proven efficacy in humoral immunity induction. However, inherent limitations activating cellular pose critical challenges for development. In this study, chiral flower‐like aluminum oxyhydroxide (AlOOH) supraparticles (SPs) are synthesized via a one‐pot hydrothermal method using cysteine (Cys) enantiomers as ligands, achieving g‐factor of 0.004. L‐AlOOH SPs (L‐SPs) demonstrate significantly greater enhancement dendritic cell (DC) maturation and antigen cross‐presentation efficiency compared D‐AlOOH (D‐SPs), indicating its potential an adjuvant. Mechanistic studies reveal that L‐SPs enter DCs Toll‐like receptor 2 (TLR2), thereby enhancing NOD‐like thermal protein domain associated 3 (NLRP3) inflammasome activation. vivo experiments show generate 21.59‐fold higher OVA‐specific antibody titers than commercial adjuvants. Further L‐SPs, after mixed with H9N2 virus proteins, enhance influenza by 15.28‐fold, sustained protection, confirming translational potential. This study demonstrates the performance AlOOH simultaneously amplify immunological responses, entering it promising next‐generation adjuvant cancer immunotherapy pandemic preparedness.

Язык: Английский

Процитировано

0
Biocompatible lipid nanovehicles for preventive and therapeutic vaccine development DOI

Yaru Jia,

Ziran Zhou,

Luksika Jiramonai

и другие.

Coordination Chemistry Reviews, Год журнала: 2025, Номер 538, С. 216718 - 216718

Опубликована: Апрель 22, 2025

Язык: Английский

Процитировано

0